Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Dermatologic 4Other neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Neoplasms 12Colonic Neoplasms 9Uterine Cervical Neoplasms 7Lung Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Dysplasia 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Esophageal Neoplasms 4Brain Neoplasms 4Thrombocythemia, Essential 3Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Papillomavirus Infections 3Oropharyngeal Neoplasms 3Neuroblastoma 3Mouth Neoplasms 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Glioma 3Gallbladder Neoplasms 3Carcinoma, Hepatocellular 3

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × Watchful Waiting × Clear all
NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
1,150 enrolled 6 charts
Dermatologic

Melanoma

NCT02694965 2024-02-14

Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma

Duke University

Completed
122 enrolled
Dermatologic

Melanoma

NCT04625491 2021-02-10

Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.

Hospital Universitario Virgen de la Arrixaca

Unknown
300 enrolled
DermatologicOther neoplasm

Melanoma, Pathological Conditions, Anatomical

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡